Poor
Not Aligned
Patient Risk:
Medium
Summary
Several claims about PMDA content and Japan-specific sourcing are not supported by the provided FDA label excerpts and cannot be verified against them. Some clinical facts (active ingredient/form and DME indication) align with the provided FDA label excerpts, but the overall set includes major unsupported statements.
Category Scores
Accurate Statements
Iluvien is an intravitreal implant containing fluocinolone acetonide.
Supported by FDA label excerpt: "ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg" (Sections: 1, 3, and dosage forms/strengths excerpt).
Iluvien is used for the treatment of diabetic macular edema (DME).
Supported by FDA label excerpt: "ILUVIEN® is indicated for the treatment of diabetic macular edema (DME)..." (Section 1.1).
Unsupported Statements
In Japan, the relevant regulatory reference for Iluvien's approval status and labeling is the PMDA (Pharmaceuticals and Medical Devices Agency) database.
FDA-approved prescribing information provided does not mention PMDA or Japan regulatory databases; no label support for this claim.
The PMDA listing generally links to documents such as the official package insert (添付文書) and, depending on the product, review reports or related regulatory materials.
Not supported by the provided FDA label excerpts (no statements about PMDA listing behavior or link structure).
The PMDA package insert is a direct source to confirm who can receive the implant.
Not supported by the provided FDA label excerpts; FDA label does not reference PMDA package inserts for determining eligibility.
The PMDA package insert provides recommended dosing and injection interval.
No support in provided FDA label excerpts for PMDA content; additionally, FDA excerpt provided does not include an injection interval or dosing interval instruction beyond general administration/monitoring.
The PMDA package insert includes key warnings, including ocular risks and steroid-related risks.
Not supported by provided FDA label excerpts as a statement about PMDA package insert contents.
The PMDA package insert provides monitoring advice and contraindications.
Not supported by provided FDA label excerpts as a statement about PMDA package insert contents.
Japan-specific indication wording and restrictions come from the PMDA package insert.
Not supported by provided FDA label excerpts; FDA label does not address Japan-specific wording.
Even when the overall condition is diabetic macular edema, patient selection criteria and treatment timing can differ across jurisdictions.
Not supported by provided FDA label excerpts; no label content about cross-jurisdiction differences or timing.
Contradictions
Important Omissions
For the DME indication claim, the AI did not include the FDA-specified restriction that patients must have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
The set includes several unsupported claims about Japan/PMDA sources. The only clinically relevant on-label statements are active ingredient/form and general DME indication; however, the DME indication statement omitted an FDA-specified eligibility restriction related to prior corticosteroid response and intraocular pressure.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple claims about PMDA package insert content and Japan-specific regulatory sourcing are unsupported by the provided FDA prescribing information excerpts, and the DME indication statement omitted key FDA eligibility criteria.
Suggested Improvement
Limit label-alignment evaluation to FDA label content. If describing DME indication, include the FDA restriction that patients must have been previously treated with corticosteroids and did not have a clinically significant rise in intraocular pressure.